JP2019515676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515676A5 JP2019515676A5 JP2018555460A JP2018555460A JP2019515676A5 JP 2019515676 A5 JP2019515676 A5 JP 2019515676A5 JP 2018555460 A JP2018555460 A JP 2018555460A JP 2018555460 A JP2018555460 A JP 2018555460A JP 2019515676 A5 JP2019515676 A5 JP 2019515676A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- acid sequence
- alk7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 266
- 102100034135 Activin receptor type-1C Human genes 0.000 claims description 118
- 101710173005 Activin receptor type-1C Proteins 0.000 claims description 118
- 238000012217 deletion Methods 0.000 claims description 50
- 230000037430 deletion Effects 0.000 claims description 50
- 238000003780 insertion Methods 0.000 claims description 50
- 230000037431 insertion Effects 0.000 claims description 50
- 238000006467 substitution reaction Methods 0.000 claims description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 18
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 11
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 108010023079 activin B Proteins 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 claims description 9
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 9
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 9
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 claims description 9
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 9
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 230000004130 lipolysis Effects 0.000 claims description 9
- 108010059616 Activins Proteins 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 8
- 239000000488 activin Substances 0.000 claims description 8
- 210000000577 adipose tissue Anatomy 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 7
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 6
- 210000001789 adipocyte Anatomy 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102000023732 binding proteins Human genes 0.000 claims description 5
- 108091008324 binding proteins Proteins 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010065941 Central obesity Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000018565 Hemochromatosis Diseases 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 206010065973 Iron Overload Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000031964 Other metabolic disease Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010033307 Overweight Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000008694 endothelial dysfunction Effects 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000018191 liver inflammation Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 229940116269 uric acid Drugs 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 2
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 210000001593 brown adipocyte Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000636 white adipocyte Anatomy 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- -1 co-receptors (eg Proteins 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326313P | 2016-04-22 | 2016-04-22 | |
| US62/326,313 | 2016-04-22 | ||
| PCT/US2017/028952 WO2017185037A1 (en) | 2016-04-22 | 2017-04-21 | Alk7 binding proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515676A JP2019515676A (ja) | 2019-06-13 |
| JP2019515676A5 true JP2019515676A5 (enExample) | 2020-06-11 |
| JP7103950B2 JP7103950B2 (ja) | 2022-07-20 |
Family
ID=60089402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555460A Active JP7103950B2 (ja) | 2016-04-22 | 2017-04-21 | Ａｌｋ７結合性タンパク質及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10501547B2 (enExample) |
| EP (1) | EP3445394A4 (enExample) |
| JP (1) | JP7103950B2 (enExample) |
| KR (2) | KR102405278B1 (enExample) |
| CN (2) | CN109219446B (enExample) |
| AU (1) | AU2017252574B2 (enExample) |
| CA (1) | CA3018272A1 (enExample) |
| WO (1) | WO2017185037A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017139564A1 (en) | 2016-02-11 | 2017-08-17 | The Johns Hopkins University | Compositions and methods for targeting activin signaling to treat cancer |
| CA3018272A1 (en) | 2016-04-22 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| CN111836642A (zh) * | 2017-10-25 | 2020-10-27 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| CN119101158A (zh) * | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| CN117586412A (zh) | 2018-03-23 | 2024-02-23 | 得克萨斯州大学系统董事会 | 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法 |
| JP7617036B2 (ja) * | 2019-05-30 | 2025-01-17 | アクセレロン ファーマ インコーポレーテッド | Ａｌｋ７結合タンパク質及びその使用 |
| US20230374591A1 (en) * | 2020-10-08 | 2023-11-23 | The Trustees Of Dartmouth College | Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| WO1986005803A1 (fr) | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FI915411A7 (fi) | 1989-05-16 | 1991-11-15 | Scripps Research Inst | Heteromeeristen reseptorien koe-ekspressio |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5614609A (en) * | 1994-10-20 | 1997-03-25 | Carlos F. Ibanez | Serine threonine kinase receptor |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| CA2293693A1 (en) | 1997-06-06 | 1998-12-10 | Asat Ag Applied Science & Technology | Anti-gpiib/iiia recombinant antibodies |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004043344A2 (en) | 2002-11-07 | 2004-05-27 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| CN1802351A (zh) | 2003-06-11 | 2006-07-12 | 麦克公司 | 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物 |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| JP5362359B2 (ja) * | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2287174B8 (en) | 2008-01-18 | 2016-12-07 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibody fragments by apatite chromatography |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| WO2010065954A2 (en) | 2008-12-05 | 2010-06-10 | Abraxis Bioscience, Llc | Sparc binding peptides and uses thereof |
| CN102482339B (zh) * | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
| WO2014102399A1 (en) * | 2012-12-31 | 2014-07-03 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| HK1221908A1 (zh) | 2013-04-29 | 2017-06-16 | Adimab, Llc | 多特异(polyspecificity)试剂，其制备方法和用途 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| CN106132988A (zh) * | 2013-12-19 | 2016-11-16 | 阿尔萨尼斯生物科学有限责任公司 | 抗金黄色葡萄球菌lukgh(lukab)毒素的抗体和抗体序列 |
| KR101644043B1 (ko) | 2014-03-18 | 2016-08-01 | 한국과학기술원 | Ｒｎａ에 특이적으로 결합하는 항체 |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| CA3018272A1 (en) | 2016-04-22 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
| CN111836642A (zh) | 2017-10-25 | 2020-10-27 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
-
2017
- 2017-04-21 CA CA3018272A patent/CA3018272A1/en active Pending
- 2017-04-21 WO PCT/US2017/028952 patent/WO2017185037A1/en not_active Ceased
- 2017-04-21 EP EP17786759.5A patent/EP3445394A4/en active Pending
- 2017-04-21 KR KR1020187032416A patent/KR102405278B1/ko active Active
- 2017-04-21 AU AU2017252574A patent/AU2017252574B2/en active Active
- 2017-04-21 CN CN201780029770.0A patent/CN109219446B/zh active Active
- 2017-04-21 JP JP2018555460A patent/JP7103950B2/ja active Active
- 2017-04-21 US US15/494,081 patent/US10501547B2/en active Active
- 2017-04-21 CN CN202310225072.5A patent/CN116217731A/zh active Pending
- 2017-04-21 KR KR1020227018313A patent/KR20220080015A/ko not_active Ceased
-
2019
- 2019-11-26 US US16/696,411 patent/US11059894B2/en active Active
-
2021
- 2021-06-17 US US17/350,608 patent/US11708414B2/en active Active
-
2023
- 2023-06-20 US US18/337,737 patent/US20230416379A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515676A5 (enExample) | ||
| JP6585503B2 (ja) | ヘテロ二量体免疫グロブリン | |
| JP2021527714A (ja) | 抗ｐｄ−１抗体及びその使用 | |
| JP2024026159A5 (enExample) | ||
| CN109311971A (zh) | 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途 | |
| JP7103950B2 (ja) | Ａｌｋ７結合性タンパク質及びその使用 | |
| JP2010043089A5 (enExample) | ||
| AU2010229705A1 (en) | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination | |
| WO2013147212A1 (ja) | 新規抗Ｓｉｇｌｅｃ－１５抗体 | |
| JP2019513015A5 (enExample) | ||
| JP2013503626A (ja) | グルカゴン受容体に対する抗体と、それらの使用 | |
| WO2013147213A1 (ja) | ＣＤＲ改変抗Ｓｉｇｌｅｃ－１５抗体 | |
| JP2021500895A5 (enExample) | ||
| WO2017088782A1 (zh) | 抗pcsk9抗体及其应用 | |
| CA3192208A1 (en) | Anti-par-2 antibodies and methods of use thereof | |
| KR20200096223A (ko) | Ildr2 길항제 및 그의 조합물 | |
| IL295979A (en) | Anti-cd36 antibodies and their use for cancer treatment | |
| JP7698635B2 (ja) | 抗幹細胞因子抗体及びその使用方法 | |
| JP7510208B2 (ja) | 抗ＴｒｋＡ抗体又はその抗原結合フラグメント、その調製方法及び使用 | |
| TW202339799A (zh) | 使用抗人類ｇｐｖｉ抗體抑制血小板凝集 | |
| TW201012476A (en) | Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers | |
| RU2652880C2 (ru) | Антитело против рецептора эпидермального фактора роста | |
| CA3209827A1 (en) | Anti-tnfr2 antibody and use thereof | |
| JP7756686B2 (ja) | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 | |
| WO2021058735A1 (en) | Cancer treatment with anti-met antibody compositions |